Erysipelas secondary prevention

Revision as of 15:43, 16 September 2016 by Luke Rusowicz-Orazem (talk | contribs)
Jump to navigation Jump to search

Erysipelas Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Erysipelas from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Erysipelas secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Erysipelas secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Erysipelas secondary prevention

CDC on Erysipelas secondary prevention

Erysipelas secondary prevention in the news

Blogs on Erysipelas secondary prevention

Directions to Hospitals Treating Erysipelas

Risk calculators and risk factors for Erysipelas secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Luke Rusowicz-Orazem, B.S.

Overview

The mainstay of Erysipelas secondary prevention is antibiotic prophylaxis for severe cases with high frequency of recurrence. Phenoxymethylpenicillin, erythromycin, and benzathine penicillin have all displayed varying efficacy in preventing Erysipelas recurrence. More research is needed to determine standardized antibiotic selection, dosing, and interval of administration for universal application.

Secondary Prevention

The mainstay of Erysipelas secondary prevention is antibiotic prophylaxis for severe cases with high frequency of recurrence.

  • Phenoxymethylpenicillin or erythromycin are indicated for prophylaxis for those with severe cases and predisposition to the disease, such as venous insufficiency.[1]
  • Research on the efficacy of antibiotic prophylaxis of Erysipelas is not conclusive for complete prevention of recurrence.[2]
    • Benzathine penicillin, administered intravenously every 3 weeks for 6 months at 2.4 MU, prevented recurrence during treatment, but cessation of therapy resumed Erysipelas incidence for 25% of the patients.[3]
    • Erythromycin was shown to be effective prophylaxis throughout administration.[1][4]
    • A randomized controlled trial of phenoxymethylpenicillin and erythromycin were shown to reduce Erysipelas recurrence in patients with venous insufficiency or lymphatic congestion, but relapse still occurred in 10% of the patients in the the treatment arm.[5]
  • Efficacy of prophylaxis is dependent on dose volume, time interval of administration, and accurate identification and specification of the pathogen.[5][2]
    • Consensus for penicillin concentrations and frequency sufficient for prophylaxis is not yet established.[2]
      • More research is needed to determine the efficacy of administration every second week and every third week.
      • Doubling the dosage of Benzathine penicillin administered (usually 1.2 MU) may provide longer and more effective prophylaxis.

References

  1. 1.0 1.1 Jorup-Rönström C, Britton S (1987). "Recurrent erysipelas: predisposing factors and costs of prophylaxis". Infection. 15 (2): 105–6. PMID 3110071.
  2. 2.0 2.1 2.2 Koster JB, Kullberg BJ, van der Meer JW (2007). "Recurrent erysipelas despite antibiotic prophylaxis: an analysis from case studies". Neth J Med. 65 (3): 89–94. PMID 17387234.
  3. Duvanel T, Mérot Y, Harms M, Saurat JH (1985). "Prophylactic antibiotics in erysipelas". Lancet. 1 (8442): 1401. PMID 2861358.
  4. Kremer M, Zuckerman R, Avraham Z, Raz R (1991). "Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections". J. Infect. 22 (1): 37–40. PMID 2002231.
  5. 5.0 5.1 Sjöblom AC, Eriksson B, Jorup-Rönström C, Karkkonen K, Lindqvist M (1993). "Antibiotic prophylaxis in recurrent erysipelas". Infection. 21 (6): 390–3. PMID 8132369.

Template:WH Template:WS